RxDoctor Payments Data

Ilda Molloy, MD

Orthopaedic Surgery · New Haven, CTNPI 1285097378

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $23,297 of the $36,731 with a category attached, or 63.4%. Smith+Nephew accounts for 95.4% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $17,155, more than ten times the $27 reported in 2021.

$36,731in general payments, 2019–2025

Across 68 payments — averaging $540.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$35K
  • Medical Device Business Services, Inc.$703
  • Stryker$598
  • Zimmer Biomet$174
  • Davol Inc.$121
  • Johnson & Johnson$105

What the payments were for

  • Consulting fees$23,29763%
  • Travel & lodging$5,15314%
  • Food & beverage$3,2819%
  • Education$5,00014%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,731 in reported general payments places this provider in the 85th percentile of 273 orthopaedic surgery providers in Connecticut.

See all orthopaedic surgery providers in Connecticut

Medicare billing

Part B allowed, 2024
$118,388
Medicare patients
168
Services billed
487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib28$1,203
Diclofenac Sodium13$236
Meloxicam45$136
Oxycodone Hcl14$84
Gabapentin12$32

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →